New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
07:01 EDTBLRXBioLineRx announces issuance of U.S. patent covering BL-8040 in immunotherapy
BioLineRx announced that an Issue of Notification has been received from the United States Patent and Trademark Office for U.S. Patent No. 8,663,651, which includes claims to protect the use of BL-8040ís composition for enhancing immune responses to an antigen, such as a tumor-associated antigen. The issued patent has a term extending to October 2029. This patent is part of BL-8040ís expanding patent portfolio, which includes 13 issued patents and 25 patent applications pending worldwide, providing a strong intellectual property estate around BL-8040.
News For BLRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 23, 2015
10:19 EDTBLRXBioLineRx management to meet with Roth Capital
Meetings to be held in San Francisco on November 30 and in Los Angeles on December 1 hosted by Roth Capital.
07:01 EDTBLRXBioLineRx commences Phase 1/2 trial for BL-8040
Subscribe for More Information
November 16, 2015
07:03 EDTBLRXBioLineRx says continues to pursue various collaboration agreements
Subscribe for More Information
07:02 EDTBLRXBioLineRx reports Q3 EPS (2c), three estimates (8c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use